Goldfarb Branham LLP is investigating shareholder claims due to the buyout of Abraxis Bioscience (NASDAQ: ABII) to Celgene (NASDAQ: CELG). The national securities litigation firm is examining the potential unfairness of the price and process. Shareholders with information or concerns are urged to contact attorney Hamilton Lindley at 877-583-2855 or email@example.com. “Abraxane, a breast cancer treatment drug produced by the company, experienced a 25% increase in revenue in the first quarter alone,” says shareholder attorney Hamilton Lindley. “If this buyout is approved, Celenge will experience this growth, while Abraxis shareholders will be paid $58 in cash plus 0.2617 shares for each share of Abraxis they own.” Goldfarb Branham LLP lawyers have significant success representing investors involved in unfair buyouts nationwide. The firm’s lawyers have been counsel on over 100 securities cases and provide nimble, creative and effective counsel at all stages of complex litigation. For more information on the buyout and your rights, you are encouraged to contact Hamilton Lindley at 877-583-2855 or firstname.lastname@example.org.